Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF

24.43
-0.0928-0.38%
Volume:144
Turnover:4K
Market Cap:5.62M
PE:- -
High:24.52
Open:24.52
Low:24.43
Close:24.52
52wk High:27.94
52wk Low:22.89
Shares:230.00K
Float Shares:230.00K
Volume Ratio:0.13
T/O Rate:0.06%
Dividend:0.41
Dividend Rate:1.69%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

OverviewCompanyNewsFilings

Former Eli Lilly Exec Sells Wyoming Estate for Close to $39.5 Million

Dow Jones
·
Oct 03

Eli Lilly announces FDA approves additional indication for Jaypirca

TIPRANKS
·
Oct 03

Lilly Says FDA Approves Expanded First-Line Cll/sll Use for Jaypirca

Reuters
·
Oct 03

Lilly's Jaypirca (Pirtobrutinib), the First-and-Only Approved Non-Covalent Btk Inhibitor, Receives Expanded Indication from U.S. FDA for Certain Patients with Previously Untreated Cll/Sll

THOMSON REUTERS
·
Oct 03

Novo Nordisk Tests Zenagamtide Dosing to Sharpen Its Obesity Drug Pipeline

TIPRANKS
·
Oct 03

Novo Nordisk A/S Series B Stock Falls Friday, Underperforms Market

Dow Jones
·
Oct 03

Moderately bullish activity in Novo Nordisk with shares up 0.39%

TIPRANKS
·
Oct 02

Correction: Top Midday Decliners

MT Newswires Live
·
Oct 02

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Oct 02

Sector Update: Healthcare

MT Newswires Live
·
Oct 02

Trump Medicare Drug Pricing Model May Apply to Only Four Companies After Exemptions

Reuters
·
Oct 02

Eli Lilly's Obesity Data Support Broader Portfolio Beyond Tirzepatide, UBS Says

MT Newswires Live
·
Oct 02

Eli Lilly (LLY) Ends Cancer Development Deal with Foghorn Therapeutics

TIPRANKS
·
Oct 01

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF), Sagimet Biosciences, Inc. Class A (SGMT) and Eli Lilly & Co (LLY)

TIPRANKS
·
Oct 01

Foghorn Therapeutics Slashes Jobs After Ending Cancer Drug Trials with Ely Lilly

Dow Jones
·
Oct 01

Lilly Says Foundayo Cuts Predicted 10-Year Type 2 Diabetes Risk 57% in Attain-1 Post-Hoc Analysis

Reuters
·
Oct 01

Eli Lilly - Foundayo 17.2 Mg Associated with 57% Reduction in Diabetes Risk, 18% in Cardiovascular Risk Versus Placebo

Reuters
·
Oct 01

Eli Lilly - Foundayo Associated with Reduced Predicted Long-Term Risk of Type 2 Diabetes and Cardiovascular Disease

THOMSON REUTERS
·
Oct 01

Hims & Hers Names Kultar Garcha UK and EMEA Chief Medical Officer

Reuters
·
Oct 01

Hims & Hers Names Chief Medical Officers in the UK and Australia, Deepening Its Investment in Local Clinical Leadership

THOMSON REUTERS
·
Oct 01
More